{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:09:03Z","timestamp":1793048943007,"version":"4.5.0"},"reference-count":167,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2017,6,22]],"date-time":"2017-06-22T00:00:00Z","timestamp":1498089600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1007\/s40263-017-0450-z","type":"journal-article","created":{"date-parts":[[2017,6,22]],"date-time":"2017-06-22T07:23:49Z","timestamp":1498116229000},"page":"551-570","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":65,"title":["Dopaminergic Therapies for Non-motor Symptoms in Parkinson\u2019s Disease"],"prefix":"10.1007","volume":"31","author":[{"given":"Eva","family":"Schaeffer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,6,22]]},"reference":[{"issue":"2","key":"450_CR1","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1620\/tjem.232.129","volume":"232","author":"H Zhang","year":"2014","unstructured":"Zhang H, Gu Z, An J, Wang C, Chan P. Non-motor symptoms in treated and untreated Chinese patients with early Parkinson\u2019s disease. Tohoku J Exp Med. 2014;232(2):129\u201336.","journal-title":"Tohoku J Exp Med"},{"issue":"1","key":"450_CR2","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1136\/jnnp-2012-303419","volume":"84","author":"R Erro","year":"2013","unstructured":"Erro R, Picillo M, Vitale C, Amboni M, Moccia M, Longo K, et al. Non-motor symptoms in early Parkinson\u2019s disease: a 2-year follow-up study on previously untreated patients. J Neurol Neurosurg Psychiatry. 2013;84(1):14\u20137.","journal-title":"J Neurol Neurosurg Psychiatry."},{"issue":"3","key":"450_CR3","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1212\/WNL.59.3.408","volume":"59","author":"T Witjas","year":"2002","unstructured":"Witjas T, Kaphan E, Azulay JP, Blin O, Ceccaldi M, Pouget J, et al. Nonmotor fluctuations in Parkinson\u2019s disease: frequent and disabling. Neurology. 2002;59(3):408\u201313.","journal-title":"Neurology."},{"issue":"13","key":"450_CR4","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12955-015-0281-x","volume":"20","author":"L Kadastik-Eerme","year":"2015","unstructured":"Kadastik-Eerme L, Rosenthal M, Paju T, Muldmaa M, Taba P. Health-related quality of life in Parkinson\u2019s disease: a cross-sectional study focusing on non-motor symptoms. Health Qual Life Outcomes. 2015;20(13):83.","journal-title":"Health Qual Life Outcomes."},{"issue":"5","key":"450_CR5","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/ene.12950","volume":"23","author":"KM Prakash","year":"2016","unstructured":"Prakash KM, Nadkarni NV, Lye WK, Yong MH, Tan EK. The impact of non-motor symptoms on the quality of life of Parkinson\u2019s disease patients: a longitudinal study. Eur J Neurol. 2016;23(5):854\u201360.","journal-title":"Eur J Neurol."},{"issue":"11","key":"450_CR6","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1002\/mds.20582","volume":"20","author":"C Pacchetti","year":"2005","unstructured":"Pacchetti C, Manni R, Zangaglia R, Mancini F, Marchioni E, Tassorelli C, et al. Relationship between hallucinations, delusions, and rapid eye movement sleep behavior disorder in Parkinson\u2019s disease. Mov Disord. 2005;20(11):1439\u201348.","journal-title":"Mov Disord."},{"issue":"Suppl. 3","key":"450_CR7","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1002\/mds.23884","volume":"26","author":"K Seppi","year":"2011","unstructured":"Seppi K, Weintraub D, Coelho M, Perez-Lloret S, Fox SH, Katzenschlager R, et al. The movement disorder society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson\u2019s disease. Mov Disord. 2011;26(Suppl. 3):S42\u201380.","journal-title":"Mov Disord."},{"issue":"1","key":"450_CR8","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.parkreldis.2012.08.004","volume":"19","author":"M Seki","year":"2013","unstructured":"Seki M, Takahashi K, Uematsu D, Mihara B, Morita Y, Isozumi K, et al. Clinical features and varieties of non-motor fluctuations in Parkinson\u2019s disease: a Japanese multicenter study. Parkinsonism Relat Disord. 2013;19(1):104\u20138.","journal-title":"Parkinsonism Relat Disord."},{"key":"450_CR9","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.clineuro.2014.10.006","volume":"127","author":"L Brun","year":"2014","unstructured":"Brun L, Lefaucheur R, Fetter D, Derrey S, Borden A, Wallon D, et al. Non-motor fluctuations in Parkinson\u2019s disease: prevalence, characteristics and management in a large cohort of parkinsonian outpatients. Clin Neurol Neurosurg. 2014;127:93\u20136.","journal-title":"Clin Neurol Neurosurg."},{"issue":"2","key":"450_CR10","doi-asserted-by":"crossref","first-page":"144","DOI":"10.4103\/0253-7176.155611","volume":"37","author":"B Menon","year":"2015","unstructured":"Menon B, Nayar R, Kumar S, Cherkil S, Venkatachalam A, Surendran K, et al. Parkinson\u2019s disease, depression, and quality-of-life. Indian J Psychol Med. 2015;37(2):144\u20138.","journal-title":"Indian J Psychol Med"},{"issue":"2","key":"450_CR11","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1176\/jnp.13.2.187","volume":"13","author":"JR Slaughter","year":"2001","unstructured":"Slaughter JR, Slaughter KA, Nichols D, Holmes SE, Martens MP. Prevalence, clinical manifestations, etiology, and treatment of depression in Parkinson\u2019s disease. J Neuropsychiatry Clin Neurosci. 2001;13(2):187\u201396.","journal-title":"J Neuropsychiatry Clin Neurosci"},{"issue":"1","key":"450_CR12","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1017\/S0033291799003141","volume":"31","author":"A Schrag","year":"2001","unstructured":"Schrag A, Jahanshahi M, Quinn NP. What contributes to depression in Parkinson\u2019s disease? Psychol Med. 2001;31(1):65\u201373.","journal-title":"Psychol Med."},{"issue":"13","key":"450_CR13","doi-asserted-by":"crossref","first-page":"965","DOI":"10.2165\/00023210-200317130-00003","volume":"17","author":"H Reichmann","year":"2003","unstructured":"Reichmann H, Brecht MH, Koster J, Kraus PH, Lemke MR. Pramipexole in routine clinical practice: a prospective observational trial in Parkinson\u2019s disease. CNS Drugs. 2003;17(13):965\u201373.","journal-title":"CNS Drugs."},{"issue":"2","key":"450_CR14","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1176\/jnp.17.2.214","volume":"17","author":"MR Lemke","year":"2005","unstructured":"Lemke MR, Brecht HM, Koester J, Kraus PH, Reichmann H. Anhedonia, depression, and motor functioning in Parkinson\u2019s disease during treatment with pramipexole. J Neuropsychiatry Clin Neurosci. 2005;17(2):214\u201320.","journal-title":"J Neuropsychiatry Clin Neurosci"},{"issue":"6","key":"450_CR15","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S1474-4422(10)70106-X","volume":"9","author":"P Barone","year":"2010","unstructured":"Barone P, Poewe W, Albrecht S, Debieuvre C, Massey D, Rascol O, et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9(6):573\u201380.","journal-title":"Lancet Neurol."},{"issue":"5","key":"450_CR16","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s00415-006-0067-5","volume":"253","author":"P Barone","year":"2006","unstructured":"Barone P, Scarzella L, Marconi R, Antonini A, Morgante L, Bracco F, et al. Pramipexole versus sertraline in the treatment of depression in Parkinson\u2019s disease: a national multicenter parallel-group randomized study. J Neurol. 2006;253(5):601\u20137.","journal-title":"J Neurol."},{"issue":"14","key":"450_CR17","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1212\/01.wnl.0000258660.74391.c1","volume":"68","author":"R Pahwa","year":"2007","unstructured":"Pahwa R, Stacy MA, Factor SA, Lyons KE, Stocchi F, Hersh BP, et al. Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease. Neurology. 2007;68(14):1108\u201315.","journal-title":"Neurology."},{"issue":"1","key":"450_CR18","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/mds.23441","volume":"26","author":"C Trenkwalder","year":"2011","unstructured":"Trenkwalder C, Kies B, Rudzinska M, Fine J, Nikl J, Honczarenko K, et al. Rotigotine effects on early morning motor function and sleep in Parkinson\u2019s disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord. 2011;26(1):90\u20139.","journal-title":"Mov Disord."},{"issue":"Pt 5","key":"450_CR19","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1093\/brain\/awt067","volume":"136","author":"S Thobois","year":"2013","unstructured":"Thobois S, Lhommee E, Klinger H, Ardouin C, Schmitt E, Bichon A, et al. Parkinsonian apathy responds to dopaminergic stimulation of D2\/D3 receptors with piribedil. Brain. 2013;136(Pt 5):1568\u201377.","journal-title":"Brain."},{"issue":"4","key":"450_CR20","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1046\/j.1468-1331.2003.00612.x","volume":"10","author":"I Rektorova","year":"2003","unstructured":"Rektorova I, Rektor I, Bares M, Dostal V, Ehler E, Fanfrdlova Z, et al. Pramipexole and pergolide in the treatment of depression in Parkinson\u2019s disease: a national multicentre prospective randomized study. Eur J Neurol. 2003;10(4):399\u2013406.","journal-title":"Eur J Neurol."},{"issue":"1\u20132","key":"450_CR21","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jns.2012.07.015","volume":"320","author":"RL Drijgers","year":"2012","unstructured":"Drijgers RL, Verhey FR, Tissingh G, van Domburg PH, Aalten P, Leentjens AF. The role of the dopaminergic system in mood, motivation and cognition in Parkinson\u2019s disease: a double blind randomized placebo-controlled experimental challenge with pramipexole and methylphenidate. J Neurol Sci. 2012;320(1\u20132):121\u20136.","journal-title":"J Neurol Sci."},{"issue":"4","key":"450_CR22","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1136\/jnnp.63.4.547","volume":"63","author":"EN Steur","year":"1997","unstructured":"Steur EN, Ballering LA. Moclobemide and selegeline in the treatment of depression in Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry. 1997;63(4):547.","journal-title":"J Neurol Neurosurg Psychiatry."},{"issue":"3","key":"450_CR23","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/WNF.0b013e31823b1da8","volume":"35","author":"A Korchounov","year":"2012","unstructured":"Korchounov A, Winter Y, Rossy W. Combined beneficial effect of rasagiline on motor function and depression in de novo PD. Clin Neuropharmacol. 2012;35(3):121\u20134.","journal-title":"Clin Neuropharmacol"},{"issue":"11","key":"450_CR24","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1176\/appi.ajp.159.11.1869","volume":"159","author":"JA Bodkin","year":"2002","unstructured":"Bodkin JA, Amsterdam JD. Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallel-group study in outpatients. Am J Psychiatry. 2002;159(11):1869\u201375.","journal-title":"Am J Psychiatry."},{"issue":"1","key":"450_CR25","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S0022-510X(99)00198-7","volume":"172","author":"C Choi","year":"2000","unstructured":"Choi C, Sohn YH, Lee JH, Kim J. The effect of long-term levodopa therapy on depression level in de novo patients with Parkinson\u2019s disease. J Neurol Sci. 2000;172(1):12\u20136.","journal-title":"J Neurol Sci."},{"issue":"2","key":"450_CR26","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/mds.870050210","volume":"5","author":"MA Menza","year":"1990","unstructured":"Menza MA, Sage J, Marshall E, Cody R, Duvoisin R. Mood changes and \u201con-off\u201d phenomena in Parkinson\u2019s disease. Mov Disord. 1990;5(2):148\u201351.","journal-title":"Mov Disord."},{"issue":"1","key":"450_CR27","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1600-0404.1993.tb04068.x","volume":"87","author":"A Vazquez","year":"1993","unstructured":"Vazquez A, Jimenez-Jimenez FJ, Garcia-Ruiz P, Garcia-Urra D. \u201cPanic attacks\u201d in Parkinson\u2019s disease: a long-term complication of levodopa therapy. Acta Neurol Scand. 1993;87(1):14\u20138.","journal-title":"Acta Neurol Scand."},{"issue":"1","key":"450_CR28","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/mds.21205","volume":"22","author":"J Kulisevsky","year":"2007","unstructured":"Kulisevsky J, Pascual-Sedano B, Barbanoj M, Gironell A, Pagonabarraga J, Garcia-Sanchez C. Acute effects of immediate and controlled-release levodopa on mood in Parkinson\u2019s disease: a double-blind study. Mov Disord. 2007;22(1):62\u20137.","journal-title":"Mov Disord."},{"issue":"9","key":"450_CR29","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1212\/WNL.45.9.1757","volume":"45","author":"RA Maricle","year":"1995","unstructured":"Maricle RA, Nutt JG, Valentine RJ, Carter JH. Dose-response relationship of levodopa with mood and anxiety in fluctuating Parkinson\u2019s disease: a double-blind, placebo-controlled study. Neurology. 1995;45(9):1757\u201360.","journal-title":"Neurology."},{"key":"450_CR30","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.parkreldis.2017.02.001","volume":"37","author":"A Juhasz","year":"2017","unstructured":"Juhasz A, Aschermann Z, Acs P, Janszky J, Kovacs M, Makkos A, et al. Levodopa\/carbidopa intestinal gel can improve both motor and non-motor experiences of daily living in Parkinson\u2019s disease: an open-label study. Parkinsonism Relat Disord. 2017;37:79\u201386.","journal-title":"Parkinsonism Relat Disord."},{"issue":"1","key":"450_CR31","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s13760-015-0497-x","volume":"116","author":"F Bellante","year":"2016","unstructured":"Bellante F, Dethy S, Zegers de Beyl D. Depression, anxiety and non-motor symptoms on initiation of intrajejunal levodopa\/carbidopa therapy. Acta Neurol Belg. 2016;116(1):39\u201341.","journal-title":"Acta Neurol Belg."},{"issue":"3","key":"450_CR32","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/wnf.0b013e31814b113e","volume":"31","author":"K Eggert","year":"2008","unstructured":"Eggert K, Schrader C, Hahn M, Stamelou M, Russmann A, Dengler R, et al. Continuous jejunal levodopa infusion in patients with advanced parkinson disease: practical aspects and outcome of motor and non-motor complications. Clin Neuropharmacol. 2008;31(3):151\u201366.","journal-title":"Clin Neuropharmacol"},{"issue":"10","key":"450_CR33","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1002\/mds.20527","volume":"20","author":"D Aarsland","year":"2005","unstructured":"Aarsland D, Zaccai J, Brayne C. A systematic review of prevalence studies of dementia in Parkinson\u2019s disease. Mov Disord. 2005;20(10):1255\u201363.","journal-title":"Mov Disord."},{"issue":"1","key":"450_CR34","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.parkreldis.2012.07.008","volume":"19","author":"RP Munhoz","year":"2013","unstructured":"Munhoz RP, Espay AJ, Morgante F, Li JY, Teive HA, Dunn E, et al. Long-duration Parkinson\u2019s disease: role of lateralization of motor features. Parkinsonism Relat Disord. 2013;19(1):77\u201380.","journal-title":"Parkinsonism Relat Disord."},{"issue":"20","key":"450_CR35","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1212\/WNL.0b013e3181fd6158","volume":"75","author":"CG Goetz","year":"2010","unstructured":"Goetz CG, Ouyang B, Negron A, Stebbins GT. Hallucinations and sleep disorders in PD: ten-year prospective longitudinal study. Neurology. 2010;75(20):1773\u20139.","journal-title":"Neurology."},{"issue":"Pt 4","key":"450_CR36","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1093\/brain\/123.4.733","volume":"123","author":"G Fenelon","year":"2000","unstructured":"Fenelon G, Mahieux F, Huon R, Ziegler M. Hallucinations in Parkinson\u2019s disease: prevalence, phenomenology and risk factors. Brain. 2000;123(Pt 4):733\u201345.","journal-title":"Brain."},{"issue":"12","key":"450_CR37","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1002\/mds.23835","volume":"26","author":"CG Goetz","year":"2011","unstructured":"Goetz CG, Stebbins GT, Ouyang B. Visual plus nonvisual hallucinations in Parkinson\u2019s disease: development and evolution over 10 years. Mov Disord. 2011;26(12):2196\u2013200.","journal-title":"Mov Disord."},{"issue":"2","key":"450_CR38","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1002\/ana.10078","volume":"51","author":"VS Mattay","year":"2002","unstructured":"Mattay VS, Tessitore A, Callicott JH, Bertolino A, Goldberg TE, Chase TN, et al. Dopaminergic modulation of cortical function in patients with Parkinson\u2019s disease. Ann Neurol. 2002;51(2):156\u201364.","journal-title":"Ann Neurol."},{"issue":"1\u20133","key":"450_CR39","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.brainresbull.2007.05.009","volume":"74","author":"F Fera","year":"2007","unstructured":"Fera F, Nicoletti G, Cerasa A, Romeo N, Gallo O, Gioia MC, et al. Dopaminergic modulation of cognitive interference after pharmacological washout in Parkinson\u2019s disease. Brain Res Bull. 2007;74(1\u20133):75\u201383.","journal-title":"Brain Res Bull."},{"issue":"Pt 3","key":"450_CR40","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1093\/brain\/awf052","volume":"125","author":"R Cools","year":"2002","unstructured":"Cools R, Stefanova E, Barker RA, Robbins TW, Owen AM. Dopaminergic modulation of high-level cognition in Parkinson\u2019s disease: the role of the prefrontal cortex revealed by PET. Brain. 2002;125(Pt 3):584\u201394.","journal-title":"Brain."},{"issue":"Pt 6","key":"450_CR41","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1093\/brain\/115.6.1701","volume":"115","author":"JA Cooper","year":"1992","unstructured":"Cooper JA, Sagar HJ, Doherty SM, Jordan N, Tidswell P, Sullivan EV. Different effects of dopaminergic and anticholinergic therapies on cognitive and motor function in Parkinson\u2019s disease: a follow-up study of untreated patients. Brain. 1992;115(Pt 6):1701\u201325.","journal-title":"Brain."},{"key":"450_CR42","doi-asserted-by":"crossref","first-page":"260896","DOI":"10.1155\/2014\/260896","volume":"2014","author":"A Costa","year":"2014","unstructured":"Costa A, Peppe A, Mazzu I, Longarzo M, Caltagirone C, Carlesimo GA. Dopamine treatment and cognitive functioning in individuals with Parkinson\u2019s disease: the \u201ccognitive flexibility\u201d hypothesis seems to work. Behav Neurol. 2014;2014:260896.","journal-title":"Behav Neurol."},{"issue":"1\u20132","key":"450_CR43","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jns.2006.05.027","volume":"248","author":"M Relja","year":"2006","unstructured":"Relja M, Klepac N. A dopamine agonist, pramipexole, and cognitive functions in Parkinson\u2019s disease. J Neurol Sci. 2006;248(1\u20132):251\u20134.","journal-title":"J Neurol Sci."},{"issue":"4","key":"450_CR44","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s00702-002-0811-7","volume":"110","author":"L Brusa","year":"2003","unstructured":"Brusa L, Bassi A, Stefani A, Pierantozzi M, Peppe A, Caramia MD, et al. Pramipexole in comparison to l-dopa: a neuropsychological study. J Neural Transm (Vienna). 2003;110(4):373\u201380.","journal-title":"J Neural Transm (Vienna)."},{"issue":"2","key":"450_CR45","first-page":"CD006564","volume":"16","author":"RL Stowe","year":"2008","unstructured":"Stowe RL, Ives NJ, Clarke C, van Hilten J, Ferreira J, Hawker RJ, et al. Dopamine agonist therapy in early Parkinson\u2019s disease. Cochrane Database Syst Rev. 2008;16(2):CD006564.","journal-title":"Cochrane Database Syst Rev"},{"issue":"13","key":"450_CR46","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/1471-2377-13-145","volume":"12","author":"H Sawada","year":"2013","unstructured":"Sawada H, Oeda T, Yamamoto K, Umemura A, Tomita S, Hayashi R, et al. Trigger medications and patient-related risk factors for Parkinson disease psychosis requiring anti-psychotic drugs: a retrospective cohort study. BMC Neurol. 2013;12(13):145.","journal-title":"BMC Neurol."},{"issue":"8","key":"450_CR47","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1001\/archneurol.2010.166","volume":"67","author":"EB Forsaa","year":"2010","unstructured":"Forsaa EB, Larsen JP, Wentzel-Larsen T, Goetz CG, Stebbins GT, Aarsland D, et al. A 12-year population-based study of psychosis in Parkinson disease. Arch Neurol. 2010;67(8):996\u20131001.","journal-title":"Arch Neurol."},{"issue":"11 Suppl. 5","key":"450_CR48","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1212\/WNL.56.suppl_5.S1","volume":"56","author":"CW Olanow","year":"2001","unstructured":"Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson\u2019s disease (2001): treatment guidelines. Neurology. 2001;56(11 Suppl. 5):S1\u201388.","journal-title":"Neurology."},{"issue":"Suppl. 3","key":"450_CR49","doi-asserted-by":"crossref","first-page":"S110","DOI":"10.1016\/S1353-8020(09)70794-1","volume":"15","author":"D Weintraub","year":"2009","unstructured":"Weintraub D. Impulse control disorders in Parkinson\u2019s disease: prevalence and possible risk factors. Parkinsonism Relat Disord. 2009;15(Suppl. 3):S110\u20133.","journal-title":"Parkinsonism Relat Disord."},{"issue":"5","key":"450_CR50","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1001\/archneurol.2010.65","volume":"67","author":"D Weintraub","year":"2010","unstructured":"Weintraub D, Koester J, Potenza MN, Siderowf AD, Stacy M, Voon V, et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol. 2010;67(5):589\u201395.","journal-title":"Arch Neurol."},{"issue":"4","key":"450_CR51","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/mds.20045","volume":"19","author":"AH Evans","year":"2004","unstructured":"Evans AH, Katzenschlager R, Paviour D, O\u2019Sullivan JD, Appel S, Lawrence AD, et al. Punding in Parkinson\u2019s disease: its relation to the dopamine dysregulation syndrome. Mov Disord. 2004;19(4):397\u2013405.","journal-title":"Mov Disord."},{"key":"450_CR52","doi-asserted-by":"crossref","first-page":"102","DOI":"10.3389\/fpsyt.2012.00102","volume":"3","author":"M Pettorruso","year":"2012","unstructured":"Pettorruso M, Martinotti G, Di Nicola M, Onofrj M, Di Giannantonio M, Conte G, et al. Amantadine in the treatment of pathological gambling: a case report. Front Psychiatry. 2012;3:102.","journal-title":"Front Psychiatry."},{"issue":"3","key":"450_CR53","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1002\/ana.22029","volume":"68","author":"A Thomas","year":"2010","unstructured":"Thomas A, Bonanni L, Gambi F, Di Iorio A, Onofrj M. Pathological gambling in Parkinson disease is reduced by amantadine. Ann Neurol. 2010;68(3):400\u20134.","journal-title":"Ann Neurol."},{"issue":"6","key":"450_CR54","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1002\/ana.22164","volume":"68","author":"D Weintraub","year":"2010","unstructured":"Weintraub D, Sohr M, Potenza MN, Siderowf AD, Stacy M, Voon V, et al. Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study. Ann Neurol. 2010;68(6):963\u20138.","journal-title":"Ann Neurol."},{"issue":"4","key":"450_CR55","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/ane.12307","volume":"131","author":"SM Fereshtehnejad","year":"2015","unstructured":"Fereshtehnejad SM, Shafieesabet M, Shahidi GA, Delbari A, Lokk J. Restless legs syndrome in patients with Parkinson\u2019s disease: a comparative study on prevalence, clinical characteristics, quality of life and nutritional status. Acta Neurol Scand. 2015;131(4):211\u20138.","journal-title":"Acta Neurol Scand."},{"issue":"17\u201318","key":"450_CR56","first-page":"525","volume":"145","author":"TC Wetter","year":"1995","unstructured":"Wetter TC, Trenkwalder C, Stiasny K, Pollmacher T, Kazenwadel J, Kohnen R, et al. Treatment of idiopathic and uremic restless legs syndrome with L-dopa\u2014a double-blind cross-over study. Wien Med Wochenschr. 1995;145(17\u201318):525\u20137.","journal-title":"Wien Med Wochenschr"},{"issue":"3","key":"450_CR57","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1592\/phco.29.3.255","volume":"29","author":"RA Hansen","year":"2009","unstructured":"Hansen RA, Song L, Moore CG, Gilsenan AW, Kim MM, Calloway MO, et al. Effect of ropinirole on sleep outcomes in patients with restless legs syndrome: meta-analysis of pooled individual patient data from randomized controlled trials. Pharmacotherapy. 2009;29(3):255\u201362.","journal-title":"Pharmacotherapy."},{"issue":"11","key":"450_CR58","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1002\/mds.23157","volume":"25","author":"WA Hening","year":"2010","unstructured":"Hening WA, Allen RP, Ondo WG, Walters AS, Winkelman JW, Becker P, et al. Rotigotine improves restless legs syndrome: a 6-month randomized, double-blind, placebo-controlled trial in the United States. Mov Disord. 2010;25(11):1675\u201383.","journal-title":"Mov Disord."},{"issue":"2","key":"450_CR59","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/mds.21261","volume":"22","author":"WH Oertel","year":"2007","unstructured":"Oertel WH, Stiasny-Kolster K, Bergtholdt B, Hallstrom Y, Albo J, Leissner L, et al. Efficacy of pramipexole in restless legs syndrome: a six-week, multicenter, randomized, double-blind study (effect-RLS study). Mov Disord. 2007;22(2):213\u20139.","journal-title":"Mov Disord."},{"issue":"2","key":"450_CR60","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/s00415-009-5299-8","volume":"257","author":"B Hogl","year":"2010","unstructured":"Hogl B, Garcia-Borreguero D, Kohnen R, Ferini-Strambi L, Hadjigeorgiou G, Hornyak M, et al. Progressive development of augmentation during long-term treatment with levodopa in restless legs syndrome: results of a prospective multi-center study. J Neurol. 2010;257(2):230\u20137.","journal-title":"J Neurol."},{"issue":"10","key":"450_CR61","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/j.sleep.2012.08.004","volume":"13","author":"MC Lipford","year":"2012","unstructured":"Lipford MC, Silber MH. Long-term use of pramipexole in the management of restless legs syndrome. Sleep Med. 2012;13(10):1280\u20135.","journal-title":"Sleep Med."},{"issue":"1","key":"450_CR62","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s10072-016-2744-1","volume":"38","author":"X Zhang","year":"2017","unstructured":"Zhang X, Sun X, Wang J, Tang L, Xie A. Prevalence of rapid eye movement sleep behavior disorder (RBD) in Parkinson\u2019s disease: a meta and meta-regression analysis. Neurol Sci. 2017;38(1):163\u201370.","journal-title":"Neurol Sci."},{"issue":"2","key":"450_CR63","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/BF01579073","volume":"43","author":"B Sharf","year":"1978","unstructured":"Sharf B, Moskovitz C, Lupton MD, Klawans HL. Dream phenomena induced by chronic levodopa therapy. J Neural Transm. 1978;43(2):143\u201351.","journal-title":"J Neural Transm."},{"issue":"3","key":"450_CR64","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1620\/tjem.226.177","volume":"226","author":"T Sasai","year":"2012","unstructured":"Sasai T, Inoue Y, Matsuura M. Effectiveness of pramipexole, a dopamine agonist, on rapid eye movement sleep behavior disorder. Tohoku J Exp Med. 2012;226(3):177\u201381.","journal-title":"Tohoku J Exp Med."},{"issue":"2","key":"450_CR65","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.parkreldis.2012.08.010","volume":"19","author":"T Sasai","year":"2013","unstructured":"Sasai T, Matsuura M, Inoue Y. Factors associated with the effect of pramipexole on symptoms of idiopathic REM sleep behavior disorder. Parkinsonism Relat Disord. 2013;19(2):153\u20137.","journal-title":"Parkinsonism Relat Disord."},{"issue":"10","key":"450_CR66","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1212\/WNL.61.10.1418","volume":"61","author":"ML Fantini","year":"2003","unstructured":"Fantini ML, Gagnon JF, Filipini D, Montplaisir J. The effects of pramipexole in REM sleep behavior disorder. Neurology. 2003;61(10):1418\u201320.","journal-title":"Neurology."},{"issue":"5","key":"450_CR67","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.sleep.2006.03.018","volume":"7","author":"MH Schmidt","year":"2006","unstructured":"Schmidt MH, Koshal VB, Schmidt HS. Use of pramipexole in REM sleep behavior disorder: results from a case series. Sleep Med. 2006;7(5):418\u201323.","journal-title":"Sleep Med."},{"issue":"10","key":"450_CR68","first-page":"1418","volume":"31","author":"H Kumru","year":"2008","unstructured":"Kumru H, Iranzo A, Carrasco E, Valldeoriola F, Marti MJ, Santamaria J, et al. Lack of effects of pramipexole on REM sleep behavior disorder in Parkinson disease. Sleep. 2008;31(10):1418\u201321.","journal-title":"Sleep."},{"issue":"2","key":"450_CR69","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S0163-8343(03)00003-3","volume":"25","author":"K Yamauchi","year":"2003","unstructured":"Yamauchi K, Takehisa M, Tsuno M, Kaneda Y, Taniguchi T, Ohno H, et al. Levodopa improved rapid eye movement sleep behavior disorder with diffuse Lewy body disease. Gen Hosp Psychiatry. 2003;25(2):140\u20132.","journal-title":"Gen Hosp Psychiatry"},{"issue":"2","key":"450_CR70","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1002\/mds.870110216","volume":"11","author":"A Tan","year":"1996","unstructured":"Tan A, Salgado M, Fahn S. Rapid eye movement sleep behavior disorder preceding Parkinson\u2019s disease with therapeutic response to levodopa. Mov Disord. 1996;11(2):214\u20136.","journal-title":"Mov Disord."},{"issue":"9","key":"450_CR71","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.sleep.2012.06.009","volume":"13","author":"F Sixel-Doring","year":"2012","unstructured":"Sixel-Doring F, Trautmann E, Mollenhauer B, Trenkwalder C. Age, drugs, or disease: what alters the macrostructure of sleep in Parkinson\u2019s disease? Sleep Med. 2012;13(9):1178\u201383.","journal-title":"Sleep Med."},{"issue":"6","key":"450_CR72","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/mds.870130606","volume":"13","author":"E Tandberg","year":"1998","unstructured":"Tandberg E, Larsen JP, Karlsen K. A community-based study of sleep disorders in patients with Parkinson\u2019s disease. Mov Disord. 1998;13(6):895\u20139.","journal-title":"Mov Disord."},{"issue":"1","key":"450_CR73","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/1531-8257(199901)14:1<117::AID-MDS1019>3.0.CO;2-0","volume":"14","author":"EJ Pappert","year":"1999","unstructured":"Pappert EJ, Goetz CG, Niederman FG, Raman R, Leurgans S. Hallucinations, sleep fragmentation, and altered dream phenomena in Parkinson\u2019s disease. Mov Disord. 1999;14(1):117\u201321.","journal-title":"Mov Disord."},{"issue":"Suppl. 1","key":"450_CR74","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1007\/PL00007736","volume":"245","author":"F Grandas","year":"1998","unstructured":"Grandas F, Martinez-Martin P, Linazasoro G. Quality of life in patients with Parkinson\u2019s disease who transfer from standard levodopa to Sinemet CR: the STAR Study. The STAR Multicenter Study Group. J Neurol. 1998;245(Suppl. 1):S31\u20133.","journal-title":"J Neurol."},{"issue":"5","key":"450_CR75","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1111\/j.1365-2125.1987.tb03223.x","volume":"24","author":"AL Leeman","year":"1987","unstructured":"Leeman AL, O\u2019Neill CJ, Nicholson PW, Deshmukh AA, Denham MJ, Royston JP, et al. Parkinson\u2019s disease in the elderly: response to and optimal spacing of night time dosing with levodopa. Br J Clin Pharmacol. 1987;24(5):637\u201343.","journal-title":"Br J Clin Pharmacol."},{"issue":"4","key":"450_CR76","doi-asserted-by":"crossref","first-page":"416","DOI":"10.4103\/0972-2327.144016","volume":"17","author":"T Ferreira","year":"2014","unstructured":"Ferreira T, Prabhakar S, Kharbanda PS. Sleep disturbances in drug naive Parkinson\u2019s disease (PD) patients and effect of levodopa on sleep. Ann Indian Acad Neurol. 2014;17(4):416\u20139.","journal-title":"Ann Indian Acad Neurol."},{"issue":"12","key":"450_CR77","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1007\/s00702-010-0506-4","volume":"117","author":"N Giladi","year":"2010","unstructured":"Giladi N, Fichtner A, Poewe W, Boroojerdi B. Rotigotine transdermal system for control of early morning motor impairment and sleep disturbances in patients with Parkinson\u2019s disease. J Neural Transm (Vienna). 2010;117(12):1395\u20139.","journal-title":"J Neural Transm (Vienna)."},{"issue":"7","key":"450_CR78","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1007\/s00415-003-1086-0","volume":"250","author":"F Stocchi","year":"2003","unstructured":"Stocchi F, Vacca L, Berardelli A, Onofrj M, Manfredi M, Ruggieri S. Dual dopamine agonist treatment in Parkinson\u2019s disease. J Neurol. 2003;250(7):822\u20136.","journal-title":"J Neurol."},{"key":"450_CR79","first-page":"131508","volume":"2015","author":"J Pagonabarraga","year":"2015","unstructured":"Pagonabarraga J, Pinol G, Cardozo A, Sanz P, Puente V, Otermin P, et al. Transdermal rotigotine improves sleep fragmentation in Parkinson\u2019s disease: results of the multicenter, prospective SLEEP-FRAM study. Parkinsons Dis. 2015;2015:131508.","journal-title":"Parkinsons Dis."},{"issue":"6","key":"450_CR80","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S1474-4422(07)70108-4","volume":"6","author":"WH Poewe","year":"2007","unstructured":"Poewe WH, Rascol O, Quinn N, Tolosa E, Oertel WH, Martignoni E, et al. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson\u2019s disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol. 2007;6(6):513\u201320.","journal-title":"Lancet Neurol."},{"issue":"1","key":"450_CR81","first-page":"79","volume":"16","author":"A Fasano","year":"2012","unstructured":"Fasano A, Ricciardi L, Lena F, Bentivoglio AR, Modugno N. Intrajejunal levodopa infusion in advanced Parkinson\u2019s disease: long-term effects on motor and non-motor symptoms and impact on patient\u2019s and caregiver\u2019s quality of life. Eur Rev Med Pharmacol Sci. 2012;16(1):79\u201389.","journal-title":"Eur Rev Med Pharmacol Sci."},{"issue":"1","key":"450_CR82","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/mds.21727","volume":"23","author":"D Verbaan","year":"2008","unstructured":"Verbaan D, van Rooden SM, Visser M, Marinus J, van Hilten JJ. Nighttime sleep problems and daytime sleepiness in Parkinson\u2019s disease. Mov Disord. 2008;23(1):35\u201341.","journal-title":"Mov Disord."},{"issue":"9","key":"450_CR83","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1001\/archneur.1994.00540210094018","volume":"51","author":"B Hilten van","year":"1994","unstructured":"van Hilten B, Hoff JI, Middelkoop HA, van der Velde EA, Kerkhof GA, Wauquier A, et al. Sleep disruption in Parkinson\u2019s disease: assessment by continuous activity monitoring. Arch Neurol. 1994;51(9):922\u20138.","journal-title":"Arch Neurol."},{"issue":"8","key":"450_CR84","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1212\/01.WNL.0000158652.74601.48","volume":"64","author":"CL Comella","year":"2005","unstructured":"Comella CL, Morrissey M, Janko K. Nocturnal activity with nighttime pergolide in Parkinson disease: a controlled study using actigraphy. Neurology. 2005;64(8):1450\u20131.","journal-title":"Neurology."},{"issue":"9","key":"450_CR85","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1002\/mds.21002","volume":"21","author":"I Shpirer","year":"2006","unstructured":"Shpirer I, Miniovitz A, Klein C, Goldstein R, Prokhorov T, Theitler J, et al. Excessive daytime sleepiness in patients with Parkinson\u2019s disease: a polysomnography study. Mov Disord. 2006;21(9):1432\u20138.","journal-title":"Mov Disord."},{"issue":"3","key":"450_CR86","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1212\/WNL.58.3.460","volume":"58","author":"JJ Ferreira","year":"2002","unstructured":"Ferreira JJ, Galitzky M, Thalamas C, Tiberge M, Montastruc JL, Sampaio C, et al. Effect of ropinirole on sleep onset: a randomized, placebo-controlled study in healthy volunteers. Neurology. 2002;58(3):460\u20132.","journal-title":"Neurology."},{"issue":"3","key":"450_CR87","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1365-2125.2008.03310.x","volume":"67","author":"J Micallef","year":"2009","unstructured":"Micallef J, Rey M, Eusebio A, Audebert C, Rouby F, Jouve E, et al. Antiparkinsonian drug-induced sleepiness: a double-blind placebo-controlled study of L-dopa, bromocriptine and pramipexole in healthy subjects. Br J Clin Pharmacol. 2009;67(3):333\u201340.","journal-title":"Br J Clin Pharmacol."},{"issue":"1","key":"450_CR88","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/00002826-199901000-00004","volume":"22","author":"N Andreu","year":"1999","unstructured":"Andreu N, Chale JJ, Senard JM, Thalamas C, Montastruc JL, Rascol O. L-Dopa-induced sedation: a double-blind cross-over controlled study versus triazolam and placebo in healthy volunteers. Clin Neuropharmacol. 1999;22(1):15\u201323.","journal-title":"Clin Neuropharmacol"},{"issue":"9212","key":"450_CR89","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/S0140-6736(00)02119-X","volume":"355","author":"JJ Ferreira","year":"2000","unstructured":"Ferreira JJ, Galitzky M, Montastruc JL, Rascol O. Sleep attacks and Parkinson\u2019s disease treatment. Lancet. 2000;355(9212):1333\u20134.","journal-title":"Lancet."},{"issue":"8","key":"450_CR90","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1001\/archneur.62.8.1242","volume":"62","author":"J Avorn","year":"2005","unstructured":"Avorn J, Schneeweiss S, Sudarsky LR, Benner J, Kiyota Y, Levin R, et al. Sudden uncontrollable somnolence and medication use in Parkinson disease. Arch Neurol. 2005;62(8):1242\u20138.","journal-title":"Arch Neurol."},{"issue":"6","key":"450_CR91","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/mds.10417","volume":"18","author":"S Paus","year":"2003","unstructured":"Paus S, Brecht HM, Koster J, Seeger G, Klockgether T, Wullner U. Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson\u2019s disease. Mov Disord. 2003;18(6):659\u201367.","journal-title":"Mov Disord."},{"issue":"9","key":"450_CR92","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1212\/WNL.52.9.1908","volume":"52","author":"S Frucht","year":"1999","unstructured":"Frucht S, Rogers JD, Greene PE, Gordon MF, Fahn S. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology. 1999;52(9):1908\u201310.","journal-title":"Neurology."},{"issue":"3","key":"450_CR93","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1468-1331.2004.00971.x","volume":"12","author":"D Kaynak","year":"2005","unstructured":"Kaynak D, Kiziltan G, Kaynak H, Benbir G, Uysal O. Sleep and sleepiness in patients with Parkinson\u2019s disease before and after dopaminergic treatment. Eur J Neurol. 2005;12(3):199\u2013207.","journal-title":"Eur J Neurol."},{"issue":"2","key":"450_CR94","doi-asserted-by":"crossref","first-page":"197","DOI":"10.3233\/JPD-2011-11037","volume":"1","author":"P Martinez-Martin","year":"2011","unstructured":"Martinez-Martin P, Reddy P, Antonini A, Henriksen T, Katzenschlager R, Odin P, et al. Chronic subcutaneous infusion therapy with apomorphine in advanced Parkinson\u2019s disease compared to conventional therapy: a real life study of non motor effect. J Parkinsons Dis. 2011;1(2):197\u2013203.","journal-title":"J Parkinsons Dis."},{"issue":"10","key":"450_CR95","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1002\/mds.22596","volume":"24","author":"H Honig","year":"2009","unstructured":"Honig H, Antonini A, Martinez-Martin P, Forgacs I, Faye GC, Fox T, et al. Intrajejunal levodopa infusion in Parkinson\u2019s disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life. Mov Disord. 2009;24(10):1468\u201374.","journal-title":"Mov Disord."},{"issue":"15","key":"450_CR96","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1002\/mds.23317","volume":"25","author":"RA Hauser","year":"2010","unstructured":"Hauser RA, Schapira AH, Rascol O, Barone P, Mizuno Y, Salin L, et al. Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson\u2019s disease. Mov Disord. 2010;25(15):2542\u20139.","journal-title":"Mov Disord."},{"issue":"3","key":"450_CR97","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.nbd.2011.10.002","volume":"46","author":"R Sakakibara","year":"2012","unstructured":"Sakakibara R, Tateno F, Kishi M, Tsuyuzaki Y, Uchiyama T, Yamamoto T. Pathophysiology of bladder dysfunction in Parkinson\u2019s disease. Neurobiol Dis. 2012;46(3):565\u201371.","journal-title":"Neurobiol Dis."},{"issue":"3","key":"450_CR98","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/nau.1930120302","volume":"12","author":"B Aranda","year":"1993","unstructured":"Aranda B, Cramer P. Effects of apomorphine and L-dopa on the parkinsonian bladder. Neurourol Urodyn. 1993;12(3):203\u20139.","journal-title":"Neurourol Urodyn."},{"issue":"8626\u20138627","key":"450_CR99","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S0140-6736(88)90932-4","volume":"2","author":"TJ Christmas","year":"1988","unstructured":"Christmas TJ, Kempster PA, Chapple CR, Frankel JP, Lees AJ, Stern GM, et al. Role of subcutaneous apomorphine in parkinsonian voiding dysfunction. Lancet. 1988;2(8626\u20138627):1451\u20133.","journal-title":"Lancet"},{"issue":"1","key":"450_CR100","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/0090-4295(76)90556-2","volume":"7","author":"GS Benson","year":"1976","unstructured":"Benson GS, Raezer DM, Anderson JR, Saunders CD, Corriere JN Jr. Effect of levodopa on urinary bladder. Urology. 1976;7(1):24\u20138.","journal-title":"Urology."},{"issue":"1","key":"450_CR101","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/S0022-5347(05)00058-3","volume":"175","author":"L Brusa","year":"2006","unstructured":"Brusa L, Petta F, Pisani A, Miano R, Stanzione P, Moschella V, et al. Central acute D2 stimulation worsens bladder function in patients with mild Parkinson\u2019s disease. J Urol. 2006;175(1):202\u20136 (discussion 6\u20137).","journal-title":"J Urol"},{"issue":"5","key":"450_CR102","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/mds.10403","volume":"18","author":"T Uchiyama","year":"2003","unstructured":"Uchiyama T, Sakakibara R, Hattori T, Yamanishi T. Short-term effect of a single levodopa dose on micturition disturbance in Parkinson\u2019s disease patients with the wearing-off phenomenon. Mov Disord. 2003;18(5):573\u20138.","journal-title":"Mov Disord."},{"issue":"16","key":"450_CR103","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1002\/mds.22840","volume":"24","author":"T Uchiyama","year":"2009","unstructured":"Uchiyama T, Sakakibara R, Yamamoto T, Ito T, Yamaguchi C, Awa Y, et al. Comparing bromocriptine effects with levodopa effects on bladder function in Parkinson\u2019s disease. Mov Disord. 2009;24(16):2386\u201390.","journal-title":"Mov Disord."},{"issue":"7","key":"450_CR104","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1002\/nau.20054","volume":"23","author":"K Winge","year":"2004","unstructured":"Winge K, Werdelin LM, Nielsen KK, Stimpel H. Effects of dopaminergic treatment on bladder function in Parkinson\u2019s disease. Neurourol Urodyn. 2004;23(7):689\u201396.","journal-title":"Neurourol Urodyn."},{"issue":"6","key":"450_CR105","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/j.1464-410X.1985.tb07025.x","volume":"57","author":"H Fitzmaurice","year":"1985","unstructured":"Fitzmaurice H, Fowler CJ, Rickards D, Kirby RS, Quinn NP, Marsden CD, et al. Micturition disturbance in Parkinson\u2019s disease. Br J Urol. 1985;57(6):652\u20136.","journal-title":"Br J Urol."},{"issue":"4","key":"450_CR106","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.parkreldis.2011.11.006","volume":"18","author":"JG Kalf","year":"2012","unstructured":"Kalf JG, de Swart BJ, Bloem BR, Munneke M. Prevalence of oropharyngeal dysphagia in Parkinson\u2019s disease: a meta-analysis. Parkinsonism Relat Disord. 2012;18(4):311\u20135.","journal-title":"Parkinsonism Relat Disord."},{"issue":"2","key":"450_CR107","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1474-4422(03)00307-7","volume":"2","author":"RF Pfeiffer","year":"2003","unstructured":"Pfeiffer RF. Gastrointestinal dysfunction in Parkinson\u2019s disease. Lancet Neurol. 2003;2(2):107\u201316.","journal-title":"Lancet Neurol."},{"issue":"5","key":"450_CR108","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1136\/jnnp.63.5.579","volume":"63","author":"PC Hunter","year":"1997","unstructured":"Hunter PC, Crameri J, Austin S, Woodward MC, Hughes AJ. Response of parkinsonian swallowing dysfunction to dopaminergic stimulation. J Neurol Neurosurg Psychiatry. 1997;63(5):579\u201383.","journal-title":"J Neurol Neurosurg Psychiatry."},{"issue":"10","key":"450_CR109","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1212\/WNL.39.10.1309","volume":"39","author":"M Bushmann","year":"1989","unstructured":"Bushmann M, Dobmeyer SM, Leeker L, Perlmutter JS. Swallowing abnormalities and their response to treatment in Parkinson\u2019s disease. Neurology. 1989;39(10):1309\u201314.","journal-title":"Neurology."},{"issue":"2","key":"450_CR110","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S0303-8467(97)80006-6","volume":"99","author":"JL Fuh","year":"1997","unstructured":"Fuh JL, Lee RC, Wang SJ, Lin CH, Wang PN, Chiang JH, et al. Swallowing difficulty in Parkinson\u2019s disease. Clin Neurol Neurosurg. 1997;99(2):106\u201312.","journal-title":"Clin Neurol Neurosurg."},{"issue":"6","key":"450_CR111","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/mds.870110622","volume":"11","author":"F Tison","year":"1996","unstructured":"Tison F, Wiart L, Guatterie M, Fouillet N, Lozano V, Henry P, et al. Effects of central dopaminergic stimulation by apomorphine on swallowing disorders in Parkinson\u2019s disease. Mov Disord. 1996;11(6):729\u201332.","journal-title":"Mov Disord."},{"issue":"3","key":"450_CR112","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/BF00260971","volume":"10","author":"D Fonda","year":"1995","unstructured":"Fonda D, Schwarz J, Clinnick S. Parkinsonian medication one hour before meals improves symptomatic swallowing: a case study. Dysphagia. 1995;10(3):165\u20136.","journal-title":"Dysphagia"},{"issue":"4","key":"450_CR113","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/WNF.0b013e3182575cdb","volume":"35","author":"N Nishikawa","year":"2012","unstructured":"Nishikawa N, Nagai M, Tsujii T, Iwaki H, Yabe H, Nomoto M. Coadministration of domperidone increases plasma levodopa concentration in patients with Parkinson disease. Clin Neuropharmacol. 2012;35(4):182\u20134.","journal-title":"Clin Neuropharmacol"},{"issue":"1-2","key":"450_CR114","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jns.2012.05.010","volume":"319","author":"H Doi","year":"2012","unstructured":"Doi H, Sakakibara R, Sato M, Masaka T, Kishi M, Tateno A, et al. Plasma levodopa peak delay and impaired gastric emptying in Parkinson\u2019s disease. J Neurol Sci. 2012;319(1-2):86\u20138.","journal-title":"J Neurol Sci."},{"issue":"10","key":"450_CR115","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1111\/jgs.13675","volume":"63","author":"S Shiina","year":"2015","unstructured":"Shiina S, Sakakibara R, Doi H, Tateno F, Sato M, Masaka T, et al. Levodopa does not worsen gastric emptying in Parkinson\u2019s disease. J Am Geriatr Soc. 2015;63(10):2185\u20136.","journal-title":"J Am Geriatr Soc."},{"issue":"3","key":"450_CR116","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s00415-010-5769-z","volume":"258","author":"Y Tanaka","year":"2011","unstructured":"Tanaka Y, Kato T, Nishida H, Yamada M, Koumura A, Sakurai T, et al. Is there a delayed gastric emptying of patients with early-stage, untreated Parkinson\u2019s disease? An analysis using the 13C-acetate breath test. J Neurol. 2011;258(3):421\u20136.","journal-title":"J Neurol."},{"issue":"4","key":"450_CR117","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/BF00280127","volume":"42","author":"DR Robertson","year":"1992","unstructured":"Robertson DR, Renwick AG, Macklin B, Jones S, Waller DG, George CF, et al. The influence of levodopa on gastric emptying in healthy elderly volunteers. Eur J Clin Pharmacol. 1992;42(4):409\u201312.","journal-title":"Eur J Clin Pharmacol."},{"issue":"6","key":"450_CR118","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1002\/mds.870120618","volume":"12","author":"I Soykan","year":"1997","unstructured":"Soykan I, Sarosiek I, Shifflett J, Wooten GF, McCallum RW. Effect of chronic oral domperidone therapy on gastrointestinal symptoms and gastric emptying in patients with Parkinson\u2019s disease. Mov Disord. 1997;12(6):952\u20137.","journal-title":"Mov Disord."},{"issue":"4","key":"450_CR119","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/ane.12010","volume":"127","author":"B Muller","year":"2013","unstructured":"Muller B, Assmus J, Larsen JP, Haugarvoll K, Skeie GO, Tysnes OB, et al. Autonomic symptoms and dopaminergic treatment in de novo Parkinson\u2019s disease. Acta Neurol Scand. 2013;127(4):290\u20134.","journal-title":"Acta Neurol Scand."},{"issue":"2","key":"450_CR120","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.parkreldis.2014.11.015","volume":"21","author":"G Pagano","year":"2015","unstructured":"Pagano G, Tan EE, Haider JM, Bautista A, Tagliati M. Constipation is reduced by beta-blockers and increased by dopaminergic medications in Parkinson\u2019s disease. Parkinsonism Relat Disord. 2015;21(2):120\u20135.","journal-title":"Parkinsonism Relat Disord."},{"issue":"10","key":"450_CR121","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1001\/archneur.1989.00520460037010","volume":"46","author":"SE Mathers","year":"1989","unstructured":"Mathers SE, Kempster PA, Law PJ, Frankel JP, Bartram CI, Lees AJ, et al. Anal sphincter dysfunction in Parkinson\u2019s disease. Arch Neurol. 1989;46(10):1061\u20134.","journal-title":"Arch Neurol."},{"issue":"5","key":"450_CR122","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1002\/ana.410330512","volume":"33","author":"LL Edwards","year":"1993","unstructured":"Edwards LL, Quigley EM, Harned RK, Hofman R, Pfeiffer RF. Defecatory function in Parkinson\u2019s disease: response to apomorphine. Ann Neurol. 1993;33(5):490\u20133.","journal-title":"Ann Neurol."},{"issue":"4","key":"450_CR123","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1002\/mds.20757","volume":"21","author":"MJ Nirenberg","year":"2006","unstructured":"Nirenberg MJ, Waters C. Compulsive eating and weight gain related to dopamine agonist use. Mov Disord. 2006;21(4):524\u20139.","journal-title":"Mov Disord."},{"issue":"3","key":"450_CR124","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.parkreldis.2009.10.007","volume":"16","author":"A Hand","year":"2010","unstructured":"Hand A, Gray WK, Chandler BJ, Walker RW. Sexual and relationship dysfunction in people with Parkinson\u2019s disease. Parkinsonism Relat Disord. 2010;16(3):172\u20136.","journal-title":"Parkinsonism Relat Disord."},{"issue":"2","key":"450_CR125","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1080\/00926230490258893","volume":"30","author":"G Bronner","year":"2004","unstructured":"Bronner G, Royter V, Korczyn AD, Giladi N. Sexual dysfunction in Parkinson\u2019s disease. J Sex Marital Ther. 2004;30(2):95\u2013105.","journal-title":"J Sex Marital Ther."},{"issue":"4","key":"450_CR126","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1002\/1531-8257(199907)14:4<701::AID-MDS1026>3.0.CO;2-R","volume":"14","author":"J Fine","year":"1999","unstructured":"Fine J, Lang AE. Dose-induced penile erections in response to ropinirole therapy for Parkinson\u2019s disease. Mov Disord. 1999;14(4):701\u20132.","journal-title":"Mov Disord."},{"issue":"8","key":"450_CR127","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.parkreldis.2005.03.004","volume":"11","author":"M Pohanka","year":"2005","unstructured":"Pohanka M, Kanovsky P, Bares M, Pulkrabek J, Rektor I. The long-lasting improvement of sexual dysfunction in patients with advanced, fluctuating Parkinson\u2019s disease induced by pergolide: evidence from the results of an open, prospective, one-year trial. Parkinsonism Relat Disord. 2005;11(8):509\u201312.","journal-title":"Parkinsonism Relat Disord."},{"issue":"3","key":"450_CR128","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1002\/mds.870130326","volume":"13","author":"JD O\u2019Sullivan","year":"1998","unstructured":"O\u2019Sullivan JD, Hughes AJ. Apomorphine-induced penile erections in Parkinson\u2019s disease. Mov Disord. 1998;13(3):536\u20139.","journal-title":"Mov Disord."},{"issue":"5","key":"450_CR129","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1159\/000052503","volume":"39","author":"E Dula","year":"2001","unstructured":"Dula E, Bukofzer S, Perdok R, George M, Apomorphine SLSG. Double-blind, crossover comparison of 3 mg apomorphine SL with placebo and with 4 mg apomorphine SL in male erectile dysfunction. Eur Urol. 2001;39(5):558\u201364.","journal-title":"Eur Urol"},{"issue":"1","key":"450_CR130","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/sj.ijir.3900816","volume":"14","author":"PI Lammers","year":"2002","unstructured":"Lammers PI, Rubio-Aurioles E, Castell R, Castaneda J, Ponce de Leon R, Hurley D, et al. Combination therapy for erectile dysfunction: a randomized, double blind, unblinded active-controlled, cross-over study of the pharmacodynamics and safety of combined oral formulations of apomorphine hydrochloride, phentolamine mesylate and papaverine hydrochloride in men with moderate to severe erectile dysfunction. Int J Impot Res. 2002;14(1):54\u20139.","journal-title":"Int J Impot Res"},{"issue":"5","key":"450_CR131","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/00002826-198910000-00002","volume":"12","author":"RJ Uitti","year":"1989","unstructured":"Uitti RJ, Tanner CM, Rajput AH, Goetz CG, Klawans HL, Thiessen B. Hypersexuality with antiparkinsonian therapy. Clin Neuropharmacol. 1989;12(5):375\u201383.","journal-title":"Clin Neuropharmacol."},{"issue":"6","key":"450_CR132","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.parkreldis.2005.06.005","volume":"11","author":"KJ Klos","year":"2005","unstructured":"Klos KJ, Bower JH, Josephs KA, Matsumoto JY, Ahlskog JE. Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson\u2019s disease and multiple system atrophy. Parkinsonism Relat Disord. 2005;11(6):381\u20136.","journal-title":"Parkinsonism Relat Disord."},{"issue":"10","key":"450_CR133","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1136\/jnnp.2003.029413","volume":"75","author":"LM Allcock","year":"2004","unstructured":"Allcock LM, Ullyart K, Kenny RA, Burn DJ. Frequency of orthostatic hypotension in a community based cohort of patients with Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry. 2004;75(10):1470\u20131.","journal-title":"J Neurol Neurosurg Psychiatry."},{"issue":"5","key":"450_CR134","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1136\/jnnp.63.5.584","volume":"63","author":"JM Senard","year":"1997","unstructured":"Senard JM, Rai S, Lapeyre-Mestre M, Brefel C, Rascol O, Rascol A, et al. Prevalence of orthostatic hypotension in Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry. 1997;63(5):584\u20139.","journal-title":"J Neurol Neurosurg Psychiatry."},{"issue":"8","key":"450_CR135","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.parkreldis.2014.04.007","volume":"20","author":"C Noack","year":"2014","unstructured":"Noack C, Schroeder C, Heusser K, Lipp A. Cardiovascular effects of levodopa in Parkinson\u2019s disease. Parkinsonism Relat Disord. 2014;20(8):815\u20138.","journal-title":"Parkinsonism Relat Disord."},{"issue":"10","key":"450_CR136","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1001\/archneur.57.10.1461","volume":"57","author":"K Kujawa","year":"2000","unstructured":"Kujawa K, Leurgans S, Raman R, Blasucci L, Goetz CG. Acute orthostatic hypotension when starting dopamine agonists in Parkinson\u2019s disease. Arch Neurol. 2000;57(10):1461\u20133.","journal-title":"Arch Neurol."},{"issue":"2","key":"450_CR137","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1136\/jnnp.63.2.228","volume":"63","author":"A Churchyard","year":"1997","unstructured":"Churchyard A, Mathias CJ, Boonkongchuen P, Lees AJ. Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry. 1997;63(2):228\u201334.","journal-title":"J Neurol Neurosurg Psychiatry."},{"issue":"6","key":"450_CR138","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1161\/01.HYP.0000188052.69549.e4","volume":"46","author":"DS Goldstein","year":"2005","unstructured":"Goldstein DS, Eldadah BA, Holmes C, Pechnik S, Moak J, Saleem A, et al. Neurocirculatory abnormalities in Parkinson disease with orthostatic hypotension: independence from levodopa treatment. Hypertension. 2005;46(6):1333\u20139.","journal-title":"Hypertension."},{"issue":"1","key":"450_CR139","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1212\/WNL.36.1.73","volume":"36","author":"CG Goetz","year":"1986","unstructured":"Goetz CG, Lutge W, Tanner CM. Autonomic dysfunction in Parkinson\u2019s disease. Neurology. 1986;36(1):73\u20135.","journal-title":"Neurology."},{"issue":"1","key":"450_CR140","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1600-0404.1985.tb03164.x","volume":"71","author":"C Sachs","year":"1985","unstructured":"Sachs C, Berglund B, Kaijser L. Autonomic cardiovascular responses in parkinsonism: effect of levodopa with dopa-decarboxylase inhibition. Acta Neurol Scand. 1985;71(1):37\u201342.","journal-title":"Acta Neurol Scand."},{"issue":"12","key":"450_CR141","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1002\/mds.10586","volume":"18","author":"L Swinn","year":"2003","unstructured":"Swinn L, Schrag A, Viswanathan R, Bloem BR, Lees A, Quinn N. Sweating dysfunction in Parkinson\u2019s disease. Mov Disord. 2003;18(12):1459\u201363.","journal-title":"Mov Disord."},{"issue":"2","key":"450_CR142","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s007020170088","volume":"108","author":"M Fischer","year":"2001","unstructured":"Fischer M, Gemende I, Marsch WC, Fischer PA. Skin function and skin disorders in Parkinson\u2019s disease. J Neural Transm (Vienna). 2001;108(2):205\u201313.","journal-title":"J Neural Transm (Vienna)."},{"issue":"6","key":"450_CR143","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1002\/mds.21422","volume":"22","author":"V Pursiainen","year":"2007","unstructured":"Pursiainen V, Haapaniemi TH, Korpelainen JT, Sotaniemi KA, Myllyla VV. Sweating in Parkinsonian patients with wearing-off. Mov Disord. 2007;22(6):828\u201332.","journal-title":"Mov Disord."},{"issue":"1","key":"450_CR144","first-page":"38","volume":"111","author":"OS Levin","year":"2011","unstructured":"Levin OS, Ivanov AK, Shindriaeva NN. Treatment of non-motor fluctuations with combined drug stalevo in patients with Parkinson\u2019s disease. Zh Nevrol Psikhiatr Im S S Korsakova. 2011;111(1):38\u201342.","journal-title":"Zh Nevrol Psikhiatr Im S S Korsakova."},{"issue":"4","key":"450_CR145","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1111\/j.1600-0404.2012.01648.x","volume":"126","author":"V Pursiainen","year":"2012","unstructured":"Pursiainen V, Lyytinen J, Pekkonen E. Effect of duodenal levodopa infusion on blood pressure and sweating. Acta Neurol Scand. 2012;126(4):e20\u20134.","journal-title":"Acta Neurol Scand."},{"issue":"2","key":"450_CR146","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/mds.870060211","volume":"6","author":"LL Edwards","year":"1991","unstructured":"Edwards LL, Pfeiffer RF, Quigley EM, Hofman R, Balluff M. Gastrointestinal symptoms in Parkinson\u2019s disease. Mov Disord. 1991;6(2):151\u20136.","journal-title":"Mov Disord."},{"issue":"5","key":"450_CR147","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1002\/mds.20784","volume":"21","author":"OR Tumilasci","year":"2006","unstructured":"Tumilasci OR, Cersosimo MG, Belforte JE, Micheli FE, Benarroch EE, Pazo JH. Quantitative study of salivary secretion in Parkinson\u2019s disease. Mov Disord. 2006;21(5):660\u20137.","journal-title":"Mov Disord."},{"issue":"2","key":"450_CR148","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1002\/mds.20189","volume":"20","author":"M Proulx","year":"2005","unstructured":"Proulx M, de Courval FP, Wiseman MA, Panisset M. Salivary production in Parkinson\u2019s disease. Mov Disord. 2005;20(2):204\u20137.","journal-title":"Mov Disord."},{"issue":"4","key":"450_CR149","first-page":"213","volume":"22","author":"H Bagheri","year":"1999","unstructured":"Bagheri H, Damase-Michel C, Lapeyre-Mestre M, Cismondo S, O\u2019Connell D, Senard JM, et al. A study of salivary secretion in Parkinson\u2019s disease. Clin Neuropharmacol. 1999;22(4):213\u20135.","journal-title":"Clin Neuropharmacol"},{"issue":"3","key":"450_CR150","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/1523-1747.ep12682040","volume":"60","author":"SR Kohn","year":"1973","unstructured":"Kohn SR, Pochi PE, Strauss JS, Sax DS, Feldman RG, Timberlake WH. Sebaceous gland secretion in Parkinson\u2019s disease during L-dopa treatment. J Investig Dermatol. 1973;60(3):134\u20136.","journal-title":"J Investig Dermatol."},{"issue":"16","key":"450_CR151","first-page":"879","volume":"283","author":"LC Parish","year":"1970","unstructured":"Parish LC. L-dopa for seborrheic dermatitis. N Engl J Med. 1970;283(16):879.","journal-title":"N Engl J Med."},{"issue":"10","key":"450_CR152","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1002\/mds.22142","volume":"23","author":"L Negre-Pages","year":"2008","unstructured":"Negre-Pages L, Regragui W, Bouhassira D, Grandjean H, Rascol O, DoPaMi PSG. Chronic pain in Parkinson\u2019s disease: the cross-sectional French DoPaMiP survey. Mov Disord. 2008;23(10):1361\u20139.","journal-title":"Mov Disord."},{"issue":"12","key":"450_CR153","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1002\/mds.20629","volume":"20","author":"C Brefel-Courbon","year":"2005","unstructured":"Brefel-Courbon C, Payoux P, Thalamas C, Ory F, Quelven I, Chollet F, et al. Effect of levodopa on pain threshold in Parkinson\u2019s disease: a clinical and positron emission tomography study. Mov Disord. 2005;20(12):1557\u201363.","journal-title":"Mov Disord."},{"issue":"10","key":"450_CR154","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1136\/jnnp.2007.120212","volume":"78","author":"A Gerdelat-Mas","year":"2007","unstructured":"Gerdelat-Mas A, Simonetta-Moreau M, Thalamas C, Ory-Magne F, Slaoui T, Rascol O, et al. Levodopa raises objective pain threshold in Parkinson\u2019s disease: a RIII reflex study. J Neurol Neurosurg Psychiatry. 2007;78(10):1140\u20132.","journal-title":"J Neurol Neurosurg Psychiatry."},{"issue":"1","key":"450_CR155","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/S0035-3787(07)90356-2","volume":"163","author":"T Slaoui","year":"2007","unstructured":"Slaoui T, Mas-Gerdelat A, Ory-Magne F, Rascol O, Brefel-Courbon C. Levodopa modifies pain thresholds in Parkinson\u2019s disease patients. Rev Neurol (Paris). 2007;163(1):66\u201371.","journal-title":"Rev Neurol (Paris)."},{"issue":"1","key":"450_CR156","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/mds.23406","volume":"26","author":"E Dellapina","year":"2011","unstructured":"Dellapina E, Gerdelat-Mas A, Ory-Magne F, Pourcel L, Galitzky M, Calvas F, et al. Apomorphine effect on pain threshold in Parkinson\u2019s disease: a clinical and positron emission tomography study. Mov Disord. 2011;26(1):153\u20137.","journal-title":"Mov Disord."},{"issue":"7","key":"450_CR157","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1136\/jnnp.2005.079053","volume":"77","author":"M Tinazzi","year":"2006","unstructured":"Tinazzi M, Del Vesco C, Fincati E, Ottaviani S, Smania N, Moretto G, et al. Pain and motor complications in Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry. 2006;77(7):822\u20135.","journal-title":"J Neurol Neurosurg Psychiatry."},{"issue":"3","key":"450_CR158","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s11940-004-0011-x","volume":"6","author":"JI Sage","year":"2004","unstructured":"Sage JI. Pain in Parkinson\u2019s disease. Curr Treat Options Neurol. 2004;6(3):191\u2013200.","journal-title":"Curr Treat Options Neurol."},{"issue":"3","key":"450_CR159","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/ana.410220313","volume":"22","author":"C Bulens","year":"1987","unstructured":"Bulens C, Meerwaldt JD, Van der Wildt GJ, Van Deursen JB. Effect of levodopa treatment on contrast sensitivity in Parkinson\u2019s disease. Ann Neurol. 1987;22(3):365\u20139.","journal-title":"Ann Neurol."},{"issue":"7","key":"450_CR160","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1136\/jnnp.50.7.847","volume":"50","author":"MJ Jaffe","year":"1987","unstructured":"Jaffe MJ, Bruno G, Campbell G, Lavine RA, Karson CN, Weinberger DR. Ganzfeld electroretinographic findings in parkinsonism: untreated patients and the effect of levodopa intravenous infusion. J Neurol Neurosurg Psychiatry. 1987;50(7):847\u201352.","journal-title":"J Neurol Neurosurg Psychiatry."},{"issue":"1","key":"450_CR161","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/BF02252659","volume":"7","author":"T Buttner","year":"1994","unstructured":"Buttner T, Kuhn W, Patzold T, Przuntek H. L-Dopa improves colour vision in Parkinson\u2019s disease. J Neural Transm Park Dis Dement Sect. 1994;7(1):13\u20139.","journal-title":"J Neural Transm Park Dis Dement Sect."},{"issue":"8","key":"450_CR162","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1212\/WNL.38.8.1237","volume":"38","author":"RL Doty","year":"1988","unstructured":"Doty RL, Deems DA, Stellar S. Olfactory dysfunction in parkinsonism: a general deficit unrelated to neurologic signs, disease stage, or disease duration. Neurology. 1988;38(8):1237\u201344.","journal-title":"Neurology."},{"issue":"11","key":"450_CR163","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1136\/jnnp.2009.182022","volume":"81","author":"T Saifee","year":"2010","unstructured":"Saifee T, Lees AJ, Silveira-Moriyama L. Olfactory function in Parkinson\u2019s disease in ON versus OFF states. J Neurol Neurosurg Psychiatry. 2010;81(11):1293\u20135.","journal-title":"J Neurol Neurosurg Psychiatry."},{"issue":"1","key":"450_CR164","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/jnnp.50.1.88","volume":"50","author":"NP Quinn","year":"1987","unstructured":"Quinn NP, Rossor MN, Marsden CD. Olfactory threshold in Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry. 1987;50(1):88\u20139.","journal-title":"J Neurol Neurosurg Psychiatry."},{"issue":"2","key":"450_CR165","first-page":"99","volume":"13","author":"J Roth","year":"1998","unstructured":"Roth J, Radil T, Ruzicka E, Jech R, Tichy J. Apomorphine does not influence olfactory thresholds in Parkinson\u2019s disease. Funct Neurol. 1998;13(2):99\u2013103.","journal-title":"Funct Neurol"},{"issue":"3","key":"450_CR166","doi-asserted-by":"crossref","first-page":"541","DOI":"10.3233\/JPD-140372","volume":"4","author":"P Zis","year":"2014","unstructured":"Zis P, Rizos A, Martinez-Martin P, Pal S, Silverdale M, Sharma JC, et al. Non-motor symptoms profile and burden in drug naive versus long-term Parkinson\u2019s disease patients. J Parkinsons Dis. 2014;4(3):541\u20137.","journal-title":"J Parkinsons Dis."},{"issue":"8","key":"450_CR167","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1002\/mds.22546","volume":"24","author":"A Nebe","year":"2009","unstructured":"Nebe A, Ebersbach G. Pain intensity on and off levodopa in patients with Parkinson\u2019s disease. Mov Disord. 2009;24(8):1233\u20137.","journal-title":"Mov Disord."}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40263-017-0450-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-017-0450-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-017-0450-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T23:12:34Z","timestamp":1659136354000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-017-0450-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,22]]},"references-count":167,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["450"],"URL":"https:\/\/doi.org\/10.1007\/s40263-017-0450-z","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,22]]}}}